NCT05579119View on ClinicalTrials.gov

SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)

PHASE4CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

August 14, 2023

Study Completion Date

August 24, 2023

Conditions
Type 2 Diabetes
Interventions
DRUG

Sitagliptin 100mg

Sitagliptin 100 mg po once daily.

DRUG

Glargine

Glargine once daily.

DRUG

Lispro

Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).

Trial Locations (1)

02990

"División de Investigación en Salud, Hospital de Especialidades, Centro Médico Nacional La Raza, IMSS", Mexico City

All Listed Sponsors
collaborator

National Polytechnic Institute, Mexico

OTHER

lead

"Hospital de Especialidades, Centro Medico Nacional La Raza, Instituto Mexicano del Seguro Social"

OTHER